Retatrutide: The New Weight Loss Drug Everyone Is Talking About. But can you get it? 

 

If you have been researching weight loss injections lately, you have probably come across retatrutide. The headlines have been hard to miss. “New drug produces 30% weight loss.” “The most powerful obesity treatment ever trialled.”

It sounds extraordinary. And the science behind it genuinely is impressive.

But there is a gap between what the trials are showing and what is actually available to you right now. This post sets out what retatrutide UK patients need to know, what the evidence says, and what it means for your weight loss journey today.

What Is Retatrutide?

Retatrutide is a new injectable medication developed by Eli Lilly. It is a once-weekly injection, like Mounjaro and Wegovy, but it works differently.

While Mounjaro acts on two hormone receptors (GIP and GLP-1), retatrutide acts on three: GIP, GLP-1, and glucagon. This triple action is why it is sometimes called a “triple agonist.”

The glucagon receptor is the key addition. Glucagon drives the liver to burn fat directly and raises the body’s resting energy use. This is a mechanism that existing approved medications do not have.

In theory, this should produce greater weight loss than anything currently available. In trials so far, that is exactly what has happened.

What Do the Trial Results Actually Show?

The results from the Phase 3 programme, known as TRIUMPH and TRANSCEND, have broken records.

In TRIUMPH-4 (December 2025), participants with obesity lost an average of 28.7% of their body weight over 68 weeks at the 12mg dose. That is the highest figure ever recorded for any obesity medication in a Phase 3 trial.

In TRIUMPH-1 (May 2026), the largest trial to date with 2,339 participants, average weight loss reached 25% at 80 weeks. In a subgroup with a BMI of 35 or above who continued for 104 weeks, the average reached 30.3%, with no sign of the plateau seen with earlier drugs.

To put these figures in context:

• Wegovy (semaglutide) produces around 15 to 17% weight loss
• Mounjaro (tirzepatide) produces around 22.5%
• Retatrutide at 12mg is producing 28 to 30%

That additional 6 to 8% over Mounjaro translates to real, meaningful weight loss at population scale.

In people with type 2 diabetes, the TRANSCEND-T2D-1 trial (published in the Lancet, June 2026) showed a 16.8% reduction in body weight and a 2.0% reduction in HbA1c at 40 weeks. These results outperform most existing diabetes and weight management treatments used together.

What Are the Side Effects?

The most common side effects are gastrointestinal. They tend to concentrate during dose titration before settling:

• Nausea (affecting around 42% at 12mg vs 15% on placebo)
• Diarrhoea (32%)
• Constipation (26%)
• Vomiting (25%)

These are consistent with the GLP-1 drug class and familiar in clinical practice.

There is one new safety signal that does not appear with Mounjaro or Wegovy: dysesthesia. This is a tingling or altered skin sensation, likely linked to the glucagon receptor activity. In TRIUMPH-1, it affected around 21% of participants at the 12mg dose, versus less than 1% on placebo. It appears mild to moderate in most cases, but it is a novel finding with no long-term data yet.

Heart rate increases of approximately 5-10 beats per minute were also observed, peaking at approximately 24 weeks. This matters for anyone with an existing heart rhythm condition.

Long-term data on pancreatitis risk, thyroid safety, and cardiovascular outcomes are still outstanding. The cardiovascular outcomes trial is ongoing and will take several more years to complete.

When Can UK Patients Actually Get Retatrutide?

This is where the excitement has to be tempered with reality.

Retatrutide is not approved anywhere in the world as of June 2026. It remains an investigational drug. It cannot be prescribed in the UK through any legal route outside a clinical trial.

The expected timeline for retatrutide UK availability is:

• FDA approval: NDA filing anticipated late 2026, approval expected late 2027
• MHRA approval: Likely 6 to 12 months after FDA, so late 2027 to mid-2028
• NHS access via NICE: Realistically, 2029 at the earliest, following a separate cost-effectiveness review
• Private prescribing in the UK: Possible from mid to late 2027, at an estimated cost of £800 to £1,500 per month

What About Buying It Online?

Some websites are already selling products labelled as retatrutide. These are not the same compound used in clinical trials. They are unregulated research peptides, manufactured without pharmaceutical oversight, with no guarantee of purity or dosing accuracy.

There is a more practical concern. Retatrutide is so new that the vast majority of doctors, including specialists, have no first-hand clinical experience managing its side effects. The dysesthesia signal, the heart rate changes, and any unexpected reactions are, at this stage, largely uncharted in real-world practice.

If you experience a problem after taking an unregulated product, finding a clinician who can help you manage it confidently will be very difficult.

The risk is not just what is in the product. It is that you are stepping outside any system of clinical support at exactly the moment you might need it most.

The Key Points

• Retatrutide is a triple hormone receptor agonist showing 28 to 30% average weight loss in Phase 3 trials, the highest ever recorded for an obesity drug
• A novel side effect called dysesthesia (skin tingling) affects around 1 in 5 participants at the highest dose, with no long-term data yet available
• Retatrutide is not approved in the UK, the US, or anywhere else, with the earliest realistic private access in 2027 to 2028 and NHS availability no sooner than 2029
• Products sold online claiming to be retatrutide are unregulated and carry significant safety and clinical support risks

What This Means For You

It is completely understandable to feel excited about results like these. But consider what is available to you right now.

Understanding what drives weight gain is the first step. Mounjaro and Wegovy have years of real-world safety data behind them. Thousands of UK patients are already losing significant weight with these medications, reducing their risk of diabetes, heart disease, and joint problems.

Every week spent waiting for a drug that is still 18 months to 3 years away from UK availability is a week not making progress. Starting treatment now with a proven medication produces results that compound over time, reducing your metabolic risk in ways that matter for your long-term health.

If you are thinking about weight loss medication and want to understand which option is right for your situation, a specialist consultation is the best place to start. At IM Clinic, we assess your full clinical picture and work with you to find the approach most likely to give you lasting results, with proper monitoring and support throughout.

Author: Dr Imran Mughal, Private Specialist GP

Website: www.imclinic.co.uk

Book a consultation: https://notes.thanksdoc.co.uk/book/clinic/im-clinic

References

Jastreboff AM, Kaplan LM, Frías JP et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

Giblin K, Kaplan LM, Somers VK et al. Retatrutide for the treatment of obesity, obstructive sleep apnoea and knee osteoarthritis: TRIUMPH trial design. Diabetes, Obesity and Metabolism. 2026;28(1):83-93. https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.70209

Bajaj HS, Welch M, Shah P et al. Efficacy and safety of retatrutide in people with type 2 diabetes (TRANSCEND-T2D-1). The Lancet. 2026;407:892-908. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00967-0/abstract

Eli Lilly and Company. Lilly’s triple agonist retatrutide delivered powerful weight loss in pivotal phase 3 obesity trial. Press release. May 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss

Eli Lilly and Company. Lilly’s triple agonist retatrutide delivered weight loss of up to an average of 71.2 lbs in first successful phase 3 trial. Press release. December 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average

Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038